MetaVia Inc. (NASDAQ:MTVA) Sees Large Drop in Short Interest

MetaVia Inc. (NASDAQ:MTVA) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totaling 124,038 shares, a drop of 70.1% from the June 15th total of 414,844 shares. Approximately 2.4% of the company’s shares are sold short. Based on an average daily trading volume, of 204,942 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is currently owned by institutional investors.

MetaVia Stock Performance

Shares of MTVA traded up $0.21 during mid-day trading on Monday, reaching $1.99. 8,781,047 shares of the company were exchanged, compared to its average volume of 1,977,362. MetaVia has a 52 week low of $0.97 and a 52 week high of $19.03. The stock has a market capitalization of $10.28 million, a PE ratio of -0.38 and a beta of 0.97. The business has a 50 day simple moving average of $1.90 and a two-hundred day simple moving average of $2.61.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). On average, analysts predict that MetaVia will post -2.78 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on MTVA shares. HC Wainwright reissued a “buy” rating on shares of MetaVia in a report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. Finally, Wall Street Zen upgraded shares of MetaVia to a “sell” rating in a report on Saturday, June 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average target price of $20.00.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.